On this page

Fluocinolone Acetonide

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Fluocinolone Acetonide
Generic name
Fluocinolone Acetonide
Dosage form
Ointment
Route
Topical
Marketing category
ANDA · ANDA
Labeler
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
3
Packages
6
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Fluocinolone Acetonide .25 mg/g 1191310 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Topical
Presentations
9

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
088168
Application type
ANDA · Abbreviated New Drug Application
Approval date
December 16, 1982
Sponsor
FOUGERA PHARMS INC
Products on application
1
Submissions recorded
5
Products approved under application 088168.
Product Trade name Form Strength Ingredient Status TE Flags
088168-001 FLUOCINOLONE ACETONIDE OINTMENT FLUOCINOLONE ACETONIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 088168.
Type No. Action Status Date Review
Supplement 5 Manufacturing (CMC) Approved March 7, 1996 —
Supplement 2 Manufacturing (CMC) Approved March 9, 1988 —
Supplement 4 Manufacturing (CMC) Approved May 28, 1987 —
Supplement 3 Manufacturing (CMC) Approved May 28, 1987 —
Original application 1 Approved December 16, 1982 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260223). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260223 HUMAN PRESCRIPTION DRUG · 20260128

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Fluocinolone Acetonide ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Fluocinolone Acetonide Ointment is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda/gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION: Fluocinolone Acetonide Ointment 0.025% is intended for topical administration. The active component is the corticosteroid Fluocinolone Acetonide USP (Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α,11β,16α)-. It has an empirical formula of C 24 H 30 F 2 O 6 and a molecular weight of 452.49 (CAS Registry Number 67-73-2). Each gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum. chemical structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ) .

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: Fluocinolone Acetonide Ointment USP, 0.025% 15 gram tubes, NDC 0168-0064-15 60 gram tubes, NDC 0168-0064-60 Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat. Protect from freezing. E. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville, New York 11747 I26415G R11/12 #296

Adverse event reports

Source: openFDA FAERS
4,305
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: FLUOCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
62559-299-15 62559-299 ANI Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (62559-299-15) / 15 g in 1 TUBE November 16, 2023
62559-299-60 62559-299 ANI Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (62559-299-60) / 60 g in 1 TUBE November 16, 2023
0713-0224-15 0713-0224 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0224-15) / 15 g in 1 TUBE July 26, 1988
0713-0224-60 0713-0224 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0224-60) / 60 g in 1 TUBE July 26, 1988
0168-0064-15 0168-0064 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 15 g in 1 TUBE (0168-0064-15) December 16, 1982
0168-0064-60 0168-0064 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 60 g in 1 TUBE (0168-0064-60) December 16, 1982
62559-299 62559-299 ANI Pharmaceuticals, Inc. — November 13, 2023
0713-0224 0713-0224 Cosette Pharmaceuticals, Inc. — July 26, 1988
0168-0064 0168-0064 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC — December 16, 1982

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.